HER2 Testing in Patients With Breast Cancer: Poor Correlation Between Weak Positivity by Immunohistochemistry and Gene Amplification by Fluorescence In Situ Hybridization
- 1 February 2002
- journal article
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 77 (2), 148-154
- https://doi.org/10.1016/s0025-6196(11)62329-x
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- When Is a Tumor Marker Ready for Prime Time? A Case Study of c-erbB-2 as a Predictive Factor in Breast CancerJournal of Clinical Oncology, 2001
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine, 2001
- HER2 and Choice of Adjuvant Chemotherapy for Invasive Breast Cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15JNCI Journal of the National Cancer Institute, 2000
- ErbB2 status and the benefit from two or five years of adjuvant tamoxifen in postmenopausal early stage breast cancerAnnals of Oncology, 2000
- Relevance of p185 HER-2/neu oncoprotein quantification in human primary breast carcinomaBreast Cancer Research and Treatment, 2000
- Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assaysJournal of Clinical Pathology, 2000
- HER-2/neu Assessment in Breast Cancer by Immunohistochemistry and Fluorescence In Situ Hybridization: Comparison of Results and Correlation With SurvivalMolecular Diagnosis, 2000
- Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic DiseaseJournal of Clinical Oncology, 1999
- HER-2 as a Prognostic, Predictive, and Therapeutic Target in Breast CancerCancer Control, 1999
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987